# Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma

> **NCT00911443** · PHASE2 · COMPLETED · sponsor: **sigma-tau i.f.r. S.p.A.** · enrollment: 488 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg
- **BIOLOGICAL:** Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg
- **BIOLOGICAL:** Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg
- **BIOLOGICAL:** Dacarbazine + Thymosin-alpha-1 3.2 mg
- **DRUG:** Dacarbazine + Interferon alpha

## Key facts

- **NCT ID:** NCT00911443
- **Lead sponsor:** sigma-tau i.f.r. S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 488 (ACTUAL)
- **Last updated:** 2009-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00911443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00911443, "Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00911443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*